Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)

Trial Profile

Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idasanutlin (Primary) ; Peginterferon alfa-2a
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2023 Results assessing effects of idasanutlin on phlebotomy requirements and splenomegaly presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 11 Sep 2019 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2019 Results assessing toxicity, safety and tolerability of idasanutlin in Polycythaemia-vera/Essential-thrombocythaemia patients to identify the recommended dose of this agent published in the Blood
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top